[Pharmacologic therapy of arteriosclerosis. II. New directions].
D000818:Animals; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001091:Arachidonate Lipoxygenases; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D001792:Blood Platelets / Q000473:pathology; D002784:Cholesterol / Q000096:biosynthesis; D002788:Cholesterol Esters / Q000378:metabolism; D008078:Cholesterol, LDL / Q000378:metabolism; D004790:Enzyme Induction / Q000187:drug effects; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006937:Hypercholesterolemia / Q000378:metabolism; D006938:Hyperlipoproteinemia Type II / Q000378:metabolism; D016859:Lipoxygenase Inhibitors; D008148:Lovastatin / Q000031:analogs & derivatives; D008297:Male; D008954:Models, Biological; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000473:pathology; D009281:Naphthalenes / Q000627:therapeutic use; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000096:biosynthesis; D010974:Platelet Aggregation / Q000187:drug effects; D051381:Rats; D011973:Receptors, LDL / Q000187:drug effects / Q000378:metabolism
D000924:Anticholesteremic Agents; D002788:Cholesterol Esters; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D016859:Lipoxygenase Inhibitors; D009281:Naphthalenes; D011973:Receptors, LDL; C012258:mevastatin; D002784:Cholesterol; D008148:Lovastatin; D001091:Arachidonate Lipoxygenases; D007862:Phosphatidylcholine-Sterol O-Acyltransferase
Terapéutica farmacológica de la arteriosclerosis. (II). Nuevas orientaciones.